Amphivena Therapeutics, Inc. is a private immuno-oncology company that is developing selective T cell engagers for the treatment of hematologic and solid tumors.  AMV564, our lead molecule, has demonstrated novel clinical activity by rapidly and selectively eliminating leukemic blasts and immature, granulocytic and monocytic myeloid derived suppressor cells (MDSC) while sparing normal myeloid cells, including neutrophils and monocytes.  AMV564 has an excellent safety profile that enables competitive approaches, including combination therapy, and provides a unique opportunity to explore the impact of MDSC depletion in cancer.